Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyue Mee | - |
dc.contributor.author | Choi, Eue-Keun | - |
dc.contributor.author | Park, Chan Soon | - |
dc.contributor.author | Cha, Myung-Jin | - |
dc.contributor.author | Lee, Seo-Young | - |
dc.contributor.author | Kwon, Joon-Myung | - |
dc.contributor.author | Oh, Seil | - |
dc.date.accessioned | 2024-01-09T13:36:17Z | - |
dc.date.available | 2024-01-09T13:36:17Z | - |
dc.date.issued | 2019-03 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/70279 | - |
dc.description.abstract | Background and objective Elderly patients with atrial fibrillation (AF) are known to have a high risk of stroke and bleeding. We investigated the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in octogenarian patients with non-valvular AF compared with warfarin. Methods A total of 687 octogenarian patients with AF who were administered NOACs (n = 403) or warfarin (n = 284) for stroke prevention between 2012 and 2016 were included. Thromboembolic (TE) events (stroke or systemic embolism), major bleeding events, and all-cause death were analyzed. Results The NOACs group (age 83.4 +/- 3.2 years, women 52.4%, CHA(2)DS(2)-VASc score 5.0 +/- 1.8) comprised 141 dabigatran, 158 rivaroxaban, and 104 apixaban users. Most patients from the NOACs group had been prescribed a reduced dose of medication (85.6%). During 14 +/- D18 months of follow-up periods, there were 19 TE events and 18 major bleeding events. Patients with NOAC showed a lower risk of TE (1.84 vs. 2.71 per 100 person-years, hazard ration [HR] 0.134, 95% confidence interval [CI] 0.038-0.479, P = 0.002), major bleeding (1.48 vs. 2.72 per 100 person-years, HR 0.110, 95% CI 0.024-0.493, P = 0.001), and all-cause death (2.57 vs. 3.50 per 100 person-years, HR 0.298, 95% CI 0.108-0.824, P = 0.020). Conclusion In octogenarian Asian patients with AF, NOACs might be associated with lower risks of thromboembolic events, major bleeding, and all-cause death than warfarin. Although most patients had received reduced doses, on-label use of NOACs was effective and safe. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.title | Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation | - |
dc.type | Article | - |
dc.identifier.doi | 10.1371/journal.pone.0211766 | - |
dc.identifier.bibliographicCitation | PLOS ONE, v.14, no.3 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000460638800008 | - |
dc.identifier.scopusid | 2-s2.0-85062642378 | - |
dc.citation.number | 3 | - |
dc.citation.title | PLOS ONE | - |
dc.citation.volume | 14 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordPlus | STROKE PREVENTION | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | ANTITHROMBOTIC THERAPY | - |
dc.subject.keywordPlus | CHINESE PATIENTS | - |
dc.subject.keywordPlus | WARFARIN | - |
dc.subject.keywordPlus | DABIGATRAN | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | RIVAROXABAN | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.